9/21/2025

In this article, we will be taking a look at the Top 10 AI-Powered Biotech Stocks to Buy Now. AbbVie Inc. stands second among them. AbbVie Inc. (NYSE:ABBV), a global biopharmaceutical leader known for therapies across immunology, oncology, and neuroscience, recently secured a major development for its immunology portfolio. On September 11, 2025, the company […]

Source: Yahoo

9/21/2025

AbbVie Inc. (NYSE:ABBV) is included among the 12 Best Dividend Paying Stocks to Buy Now. AbbVie Inc. (NYSE:ABBV) is a pharmaceutical company that was spun off from Abbott Laboratories in 2013 and is worth considering for a long-term portfolio. One of the strongest reasons to invest in the company is its dividend. The company’s recent […]

Source: Yahoo

9/20/2025

The bank stands to earn $130 million for work on the railroad megadeal between Union Pacific and Norfolk Southern.

Source: Yahoo

9/20/2025

Atai Life Sciences N.V. (NASDAQ:ATAI) is one of the best healthcare penny stocks to buy now. On September 15, H.C. Wainwright reiterated a ‘Buy’ rating on the stock and a $15 price target. The positive stance follows a meeting between the research firm and the company’s CEO, Srinivas Rao, at the 27th Annual Global Investment […]

Source: Yahoo

9/19/2025

With the Fed's first 2025 rate cut and upgraded growth outlook, ETFs in tech, financials, industrials and health care could benefit from momentum.

Source: Yahoo

9/19/2025

Zacks spotlights AbbVie, ServiceNow, Boeing, Tucows, and Ampco-Pittsburgh, detailing growth drivers, headwinds, and industry positioning.

Source: Yahoo

9/19/2025

Everything is going great for the stock market right now. But a plot twist could be on the way.

Source: Yahoo

9/19/2025

AstraZeneca is a leading global pharmaceutical company with strong growth in oncology, diversified revenues, and a robust pipeline. Click to read why AZN is a Buy.

Source: SeekingAlpha

9/18/2025

AbbVie, ServiceNow, and Boeing outpace their industries as analysts highlight growth drivers and risks in fresh research reports.

Source: Yahoo

9/18/2025

J&J sees Innovative Medicines growth in 2025, fueled by oncology and immunology drugs, despite steep Stelara sales erosion.

Source: Yahoo

9/18/2025

AbbVie Inc. (NYSE:ABBV) is among the high growth mega cap stocks you can buy and hold for the next 3 years. Evan Seigerman, an analyst at BMO Capital, increased the price target on AbbVie Inc. (NYSE:ABBV) to $240 from $215 with an ‘Outperform’ rating. This potential upside of nearly 10% follows the company’s announcement that […]

Source: Yahoo

9/18/2025

The Fed's 25bps cut highlights growing labor market concerns, with more cuts expected in 2025 amid shifting opportunities. Find out why safe investing still matters.

Source: SeekingAlpha

9/17/2025

The latest trading day saw AbbVie (ABBV) settling at $220.81, representing a +2.1% change from its previous close.

Source: Yahoo

9/17/2025

Biotech stock Oruka Therapeutics skyrocketed Wednesday on promising test results for what could be a once-annual shot to treat psoriasis.

Source: Yahoo

9/17/2025

Health care stocks were edging up late Wednesday afternoon, with the NYSE Health Care Index up 0.2%

Source: Yahoo

9/17/2025

AbbVie shares have hit record highs after extending Rinvoq’s patent protection to 2037, boosting confidence in future earnings and dividend growth, with analysts seeing steady fundamentals and modest upside as the company’s immunology pipeline drives results.

Source: Yahoo

9/17/2025

AbbVie Inc. stock outperforms competitors on strong trading day

Source: MarketWatch

9/17/2025

Biotech stock Oruka Therapeutics skyrocketed Wednesday on promising test results for what could be a once-annual shot to treat psoriasis.

Source: Yahoo

9/17/2025

Netflix upgraded, Five Below initiated: Wall Street's top analyst calls

Source: Yahoo

9/17/2025

Biotech stock Oruka Therapeutics skyrocketed Wednesday on promising test results for what could be a once-annual shot to treat psoriasis.

Source: Yahoo